Table 2

Univariate analysis for progression to advanced neoplasia (AN) within the discovery set

Variablen
(n=249)
HR (95% CI)P value
Female sex85/2491.1 (0.5 to 2.3)0.79
Age at LGD diagnosis (years)(n=249)
 Less than 40161
 40–59840.7 (0.2 to 3.4)0.708
 60 or more1490.7 (0.2 to 3.1)0.656
Duration of UC at LGD diagnosis (years)(n=247)
 0–10441
 11–20703.4 (0.7 to 15.1)0.116
 >201332.5 (0.6 to 10.6)0.229
Presence of concomitant PSC13/2482.6 (0.8 to 8.6)0.116
Patient exposure to 5-aminosalicylate medication(n=238)
 None documented281
 0–10 years531.4 (0.3 to 5.4)0.664
 >10 years1571.2 (0.4 to 4.2)0.729
Patient exposure to immunomodulator medication(n=237)
 None documented1711
 0–10 years432.4 (1.1 to 5.4)0.032
 >10 years230.8 (0.2 to 3.6)0.809
Macroscopic morphology of index LGD(n=247)
 Polypoid1421
 Non-polypoid872.6 (1.2 to 5.7)0.016
 Invisible184.1 (1.3 to 12.9)0.016
Visible index LGD size 10 mm or more79/2483.8 (1.8 to 7.9) 0.0004
Location of index LGD(n=243)
 Distal to splenic flexure1151
 Proximal to splenic flexure1280.7 (0.3 to 1.4)0.27
Index LGD not endoscopically resected or incomplete resection40/2494.7 (2.2 to 10) <0.0001
Multifocal LGD at index diagnosis61/2493.2 (1.6 to 6.5) 0.002
Previous diagnosis of indefinite for dysplasia12/2494.3 (1.5 to 12.5)0.007
Presence of a colonic stricture8/2495.5 (1.7 to 18.6)0.006
Scarring/tubular/shortened colon137/2491.6 (0.7 to 3.3)0.251
Moderate to severe histological active inflammation severity at time of or within previous 5 years of LGD diagnosis62/2473.6 (1.7 to 7.6) 0.0006
Cumulative inflammation burden (CIB)*
(HR per 2-unit increase in CIB)
(n=177)3.8 (1.8 to 8.0) 0.0004
Multiple postinflammatory polyps88/2411.5 (0.7 to 3.2)0.26
  • Risk factors for LGD progression to high-grade dysplasia or colorectal cancer (univariate Cox regression analysis—30/249 AN). Statistical significance required p<0.003 with Bonferroni multiple testing correction (bold values).

  • *HR per 2-unit increase in cumulative inflammatory burden (equivalent to increase of 2 years of continuous mild, 1 year of continuous moderate or 8 months of continuous severe active disease).

  • LGD, low-grade dysplasia; PSC, primary sclerosing cholangitis.